Gilead downgraded at Truist on cancer strategy [Seeking Alpha]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
company and its partner Arcus Biosciences' ( RCUS ) recently announced changes to several cancer development programs. The downgrade comes weeks after Foster City, California-based biotech made a $320M equity investment in RCUS and amended their development program for the TIGIT-targeting monoclonal antibody domvanalimab. Changes included plans to discontinue further enrollment in their Phase 3 trial called ARC-10, designed to study domvanalimab in non-small cell lung cancer (NSCLC) as a first-line combination therapy. Truist analyst Robyn Karnauskas argued that the newly prioritized Phase 3 studies, STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer), will not read out until at least 2025. Both studies are designed to evaluate domvanalimab in combination with chemotherapy and the anti-PD1 monoclonal antibody zimberelimab. The analyst called reprioritization "of chemo combos in lung and other (large) markets as smart, nimble, and cost-efficient," but argued that st
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024Business Wire
- Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingBusiness Wire
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update [Yahoo! Finance]Yahoo! Finance
RCUS
Earnings
- 2/21/24 - Beat
RCUS
Sec Filings
- 4/24/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- RCUS's page on the SEC website